Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Percheron Therapeutics ( (AU:PER) ).
Percheron Therapeutics Limited announced a significant change in the shareholding of its director, James Garner, who acquired 39,500,000 fully paid ordinary shares, increasing his total holdings to 42,500,000 shares. This acquisition, valued at $475,276.84, was conducted through on-market purchases and signifies a notable increase in director interest, potentially reflecting confidence in the company’s future prospects and impacting investor perception positively.
More about Percheron Therapeutics
Percheron Therapeutics Limited operates in the biotechnology industry, focusing on the development and commercialization of therapeutic solutions. The company is involved in the research and production of innovative medical treatments, targeting specific health conditions to improve patient outcomes.
Average Trading Volume: 10,000
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.97M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.